GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: DS-6000 | DS-6000A | R-DXd
Compound class:
Antibody
Comment: Raludotatug deruxtecan (R-DXd; DS-6000a) is an anti-CDH6 monoclonal conjugated to the chemotherapy agent deruxtecan (DXd; a derivative of the topoisomerase I inhibitor exatecan) [1-2]. The antitumour effect of raludotatug deruxtecan is due to intracellular release of the toxic payload; the naked antibody has no anti-tumour activity.
|
| References |
|
1. Chen R, Ren Z, Bai L, Hu X, Chen Y, Ye Q, Hu Y, Shi J. (2024)
Novel antibody-drug conjugates based on DXd-ADC technology. Bioorg Chem, 151: 107697. [PMID:39121594] |
|
2. Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, Kaneda Y, Nishiya Y, Honda T, Ishizaka T et al.. (2024)
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models. Mol Cancer Ther, 23 (3): 257-271. [PMID:38205802] |
|
3. Wang PH, Chang WH, Yang ST. (2026)
A potential antibody-drug conjugate targeting CDH6 (R-DXd) for chemo-resistant recurrent ovarian cancer. Taiwan J Obstet Gynecol, 65 (3): 410-412. [PMID:42036170] |
